Literature DB >> 2025957

Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension.

T Terada1, Y Nakanuma, M Hoso, H Obata.   

Abstract

Immunologic abnormalities have been reported in idiopathic portal hypertension, though the exact immunologic mechanism(s) leading to various portal venopathies in this disease remain unsettled. Recently, aberrant expression of HLA-DR antigen on target cells has been noted in the organ-specific autoimmune diseases. In this study the expression of HLA-DR antigen on the hepatic vasculature was surveyed immunohistochemically in idiopathic portal hypertension (n = 36) and in control livers: normal livers (n = 27), chronic active hepatitis (n = 35) and cirrhosis (n = 21). Endothelial cells of hepatic veins and hepatic arteries occasionally expressed HLA-DR antigen, and there was no difference in the expression between idiopathic portal hypertension and controls. Endothelial cells of the main portal vein, within the small and medium-sized portal tract, did not express HLA-DR antigen in idiopathic portal hypertension and controls. By contrast, endothelial cells of the smaller venous radicles, including inlet venules in these portal tracts other than the main portal vein, more frequently expressed HLA-DR antigen in idiopathic portal hypertension (78%) than in chronic active hepatitis (26%), cirrhosis (29%) and normal liver (15%). These data raise the possibility that the smaller venous radicles in the small and medium-sized portal tracts are targets of immunologic attack in idiopathic portal hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2025957      PMCID: PMC1535389     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Distribution of HLA-DR, HLA-DP, HLA-DQ antigens in liver tissue from patients with primary sclerosing cholangitis.

Authors:  U Broomé; H Glaumann; R Hultcrantz; U Forsum
Journal:  Scand J Gastroenterol       Date:  1990-01       Impact factor: 2.423

2.  "Idiopathic" portal hypertension due to occlusion of intrahepatic portal veins by organized thrombi. A study based on postmortem vinylite-injection corrosion and dissection of the intrahepatic vasculature in 4 cases.

Authors:  J L Boyer; M R Hales; G Klatskin
Journal:  Medicine (Baltimore)       Date:  1974-01       Impact factor: 1.889

3.  Extra- and intrahepatic portal hypertension without cirrhosis (hepatoportal sclerosis).

Authors:  W P Mikkelsen; H A Edmondson; R L Peters; A G Redeker; T B Reynolds
Journal:  Ann Surg       Date:  1965-10       Impact factor: 12.969

4.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

5.  Cellular interactions in the generation of cytolytic T lymphocyte responses: role of Ia-positive splenic adherent cells in presentation in H-2 antigen.

Authors:  O Weinberger; S H Herrmann; M F Mescher; B Benacerraf; S J Burakoff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-10       Impact factor: 11.205

6.  Idiopathic portal hypertension associated with progressive systemic sclerosis.

Authors:  K Umeyama; S Yui; A Fukamizu; K Yoshikawa; T Yamashita
Journal:  Am J Gastroenterol       Date:  1982-09       Impact factor: 10.864

7.  Slow cirrhosis--or no cirrhosis? a lesion causing benign intrahepatic portal hypertension.

Authors:  D A Levison; J G Kingham; A M Dawson; A G Stansfeld
Journal:  J Pathol       Date:  1982-07       Impact factor: 7.996

8.  Expression of Ia-like antigens in normal human nonlymphoid tissues.

Authors:  P G Natali; C De Martino; V Quaranta; M R Nicotra; F Frezza; M A Pellegrino; S Ferrone
Journal:  Transplantation       Date:  1981-01       Impact factor: 4.939

9.  Liver pathology of idiopathic portal hypertension. Comparison with non-cirrhotic portal fibrosis of India. The Japan idiopathic portal hypertension study.

Authors:  K Okuda; T Nakashima; M Okudaira; M Kage; Y Aida; M Omata; M Sugiura; H Kameda; K Inokuchi; S R Bhusnurmath; B A Aikat
Journal:  Liver       Date:  1982-09

10.  The pathology of noncirrhotic portal fibrosis: a review of 32 autopsy cases.

Authors:  B K Aikat; S R Bhusnurmath; P N Chhuttani; S K Mitra; D V Dutta
Journal:  Hum Pathol       Date:  1979-07       Impact factor: 3.466

View more
  8 in total

Review 1.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

2.  Monolobar hepatobiliary fibropolycystic disease.

Authors:  Tadashi Terada; Toshiaki Moriki
Journal:  Pathol Oncol Res       Date:  2010-05-30       Impact factor: 3.201

3.  Idiopathic portal hypertension associated with high serum titer of autoantibodies and liver dysfunction.

Authors:  K Mori; E Ishimura; H Goto; S Shoji; S Seki; T Yamashita; K Wakasa; Y Nishizawa; H Morii
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

4.  A case of small well-differentiated hepatocellular carcinoma with marked lymphocytic infiltrate.

Authors:  Tomohiro Iwasaki; Aki Kubota; Makoto Suzuki; Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2020-03-01

5.  Expression of connective tissue growth factor in the human liver with idiopathic portal hypertension.

Authors:  Hiroyasu Morikawa; Akihiro Tamori; Shuhei Nishiguchi; Masaru Enomoto; Daiki Habu; Norifumi Kawada; Susumu Shiomi
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

6.  Idiopathic portal hypertension complicating systemic sclerosis: a case report.

Authors:  John Moschos; Grigoris I Leontiadis; Clive Kelly; James Henry; Savvas Kadis
Journal:  BMC Gastroenterol       Date:  2005-05-26       Impact factor: 3.067

7.  Porto-Sinusoidal Vascular Disease in a Patient With Diffuse Aortitis and Massive Ascites.

Authors:  Emily Lin; Brian T Lee
Journal:  ACG Case Rep J       Date:  2022-07-06

8.  Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin's lymphoma to many other types of solid cancers.

Authors:  Rod Balhorn; Monique Cosman Balhorn
Journal:  Oncotarget       Date:  2020-09-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.